英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - dihydrocodeine tartrate - oral tablet - 30mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

m & a pharmachem ltd - dihydrocodeine tartrate - oral tablet - 30mg

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

galen limited - paracetamol dihydrocodeine bitartrate - tablets - 10/500 milligram

美国 - 英文 - NLM (National Library of Medicine)

mikart, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (codeine - unii:q830pw7520) - tablet - 712.8 mg - acetaminophen, caffeine and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or in any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance ma

美国 - 英文 - NLM (National Library of Medicine)

larken laboratories inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 325 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and p

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dihydrocodeine tartrate - oral solution - 2mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - dihydrocodeine tartrate - oral solution - 2mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dihydrocodeine tartrate - solution for injection - 50mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - dihydrocodeine tartrate - solution for injection - 50mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

drug tariff special order - dihydrocodeine tartrate - oral suspension - 2mg/1ml